185 related articles for article (PubMed ID: 23153426)
21. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
[TBL] [Abstract][Full Text] [Related]
22. Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy.
Turksma AW; Coupé VM; Shamier MC; Lam KL; de Weger VA; Belien JA; van den Eertwegh AJ; Meijer GA; Meijer CJ; Hooijberg E
Clin Cancer Res; 2016 Jan; 22(2):346-56. PubMed ID: 26420855
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
24. [High-throughput screening method of KRAS mutations at codons 12 and 13 in formalin-fixed paraffin-embedded tissue specimens of metastatic colorectal cancer].
Fukushima Y; Yanaka S; Murakami K; Abe Y; Koshizaka T; Hara H; Samejima C; Kishi Y; Kaneda M; Yoshino T
Gan To Kagaku Ryoho; 2011 Nov; 38(11):1825-35. PubMed ID: 22083191
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of K-ras codon 12 mutation in patients with resected gallbladder cancer.
Kazmi HR; Chandra A; Nigam J; Noushif M; Parmar D; Gupta V
Dig Surg; 2013; 30(3):233-9. PubMed ID: 23838952
[TBL] [Abstract][Full Text] [Related]
26. Local recurrence in mismatch repair-proficient colon cancer predicted by an infiltrative tumor border and lack of CD8+ tumor-infiltrating lymphocytes.
Zlobec I; Terracciano LM; Lugli A
Clin Cancer Res; 2008 Jun; 14(12):3792-7. PubMed ID: 18559598
[TBL] [Abstract][Full Text] [Related]
27. MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases.
Isella C; Mellano A; Galimi F; Petti C; Capussotti L; De Simone M; Bertotti A; Medico E; Muratore A
Ann Surg; 2013 Jun; 257(6):1089-95. PubMed ID: 23665971
[TBL] [Abstract][Full Text] [Related]
28. Impact of KRAS mutation on outcome of patients with metastatic colorectal cancer.
Chang YY; Lin JK; Lin TC; Chen WS; Jeng KJ; Yang SH; Wang HS; Lan YT; Lin CC; Liang WY; Chang SC
Hepatogastroenterology; 2014 Oct; 61(135):1946-53. PubMed ID: 25713893
[TBL] [Abstract][Full Text] [Related]
29. The frequency and spectrum of K-ras mutations among Iraqi patients with sporadic colorectal carcinoma.
Al-Allawi NA; Ismaeel AT; Ahmed NY; Merza NS
Indian J Cancer; 2012; 49(1):163-8. PubMed ID: 22842183
[TBL] [Abstract][Full Text] [Related]
30. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease.
Sträter J; Hinz U; Hasel C; Bhanot U; Mechtersheimer G; Lehnert T; Möller P
Gut; 2005 May; 54(5):661-5. PubMed ID: 15831912
[TBL] [Abstract][Full Text] [Related]
31. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.
Emile JF; Julié C; Le Malicot K; Lepage C; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Dimet S; Boulagnon-Rombi C; Allard MA; Penault-Llorca F; Bennouna J; Laurent-Puig P; Taieb J; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
Eur J Cancer; 2017 Sep; 82():16-24. PubMed ID: 28651158
[TBL] [Abstract][Full Text] [Related]
32. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
[TBL] [Abstract][Full Text] [Related]
33. Combined DNA flow cytometry and sorting with k-ras2 mutation spectrum analysis and the prognosis of human sporadic colorectal cancer.
Geido E; Sciutto A; Rubagotti A; Oliani C; Monaco R; Risio M; Giaretti W
Cytometry; 2002 Aug; 50(4):216-24. PubMed ID: 12210601
[TBL] [Abstract][Full Text] [Related]
34. Oncosuppressor methylation: a possible key role in colon metastatic progression.
Tommasi S; Pinto R; Petriella D; Pilato B; Lacalamita R; Santini D; Zito F; Colucci G; Paradiso A; Silvestris N
J Cell Physiol; 2011 Jul; 226(7):1934-9. PubMed ID: 21506124
[TBL] [Abstract][Full Text] [Related]
35. The balanced induction of K-ras codon 12 and 13 mutations in mucosa differs from their ratio in neoplastic tissues.
Kraus MC; Seelig MH; Linnemann U; Berger MR
Int J Oncol; 2006 Oct; 29(4):957-64. PubMed ID: 16964391
[TBL] [Abstract][Full Text] [Related]
36. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
Gawlick U; Lu KC; Douthit MA; Diggs BS; Schuff KG; Herzig DO; Tsikitis VL
Am J Surg; 2013 May; 205(5):608-12; discussion 612. PubMed ID: 23592171
[TBL] [Abstract][Full Text] [Related]
37. The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR.
Kobunai T; Watanabe T; Yamamoto Y; Eshima K
Biochem Biophys Res Commun; 2010 Apr; 395(1):158-62. PubMed ID: 20361930
[TBL] [Abstract][Full Text] [Related]
38. [KRAS gene mutation in colorectal cancer].
Roa I; Sánchez T; Majlis A; Schalper K
Rev Med Chil; 2013 Sep; 141(9):1166-72. PubMed ID: 24522420
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon.
Pricolo VE; Finkelstein SD; Wu TT; Keller G; Bakker A; Swalsky PA; Bland KI
Am J Surg; 1996 Jan; 171(1):41-6. PubMed ID: 8554149
[TBL] [Abstract][Full Text] [Related]
40. Influence of anatomical subsite on the incidence of microsatellite instability, and KRAS and BRAF mutation rates in patients with colon carcinoma.
Benedix F; Meyer F; Kube R; Kropf S; Kuester D; Lippert H; Roessner A; Krüger S
Pathol Res Pract; 2012 Oct; 208(10):592-7. PubMed ID: 22898351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
